Changes in inflammatory biomarkers in patients treated with ticagrelor or clopidogrel

Related Experiment Video

Updated: Jun 13, 2026

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Steen Husted1, Robert F Storey, Robert A Harrington

  • 1Arhus University Hospital, Arhus, Denmark. steehust@rm.dk

Clinical Cardiology
|April 16, 2010
PubMed

Insights

Ticagrelor and clopidogrel showed no significant differences in reducing inflammatory biomarkers like CRP and IL-6 in patients with non-ST-segment elevation acute coronary syndromes (NSTE-ACS). This study compared their anti-inflammatory effects in NSTE-ACS patients.

Area of Science:

  • Cardiology
  • Pharmacology
  • Biochemistry

Background:

  • Inflammation plays a critical role in atherosclerotic disease and acute coronary syndromes (ACS).
  • P2Y(12) receptor antagonists, ticagrelor and clopidogrel, are investigated for potential anti-inflammatory properties.
  • Biomarkers such as C-reactive protein (CRP), interleukin-6 (IL-6), myeloperoxidase (MPO), and soluble CD40 ligand (sCD40L) are key indicators of inflammation.

Purpose of the Study:

  • To compare the anti-inflammatory effects of ticagrelor versus clopidogrel in patients with non-ST-segment elevation acute coronary syndromes (NSTE-ACS).
  • To assess the impact of ticagrelor and clopidogrel on specific inflammatory biomarkers (CRP, IL-6, MPO, sCD40L).

Main Methods:

  • A double-blind, double-dummy, multicenter trial (DISPERSE 2) involving 990 NSTE-ACS patients.
  • Patients were randomized to receive ticagrelor (90 mg or 180 mg twice daily) or clopidogrel (initial 300 mg, then 75 mg daily), with or without a ticagrelor loading dose.
  • Inflammatory biomarkers were measured at baseline, discharge, and 4 weeks, alongside standard ACS treatment including aspirin.

Main Results:

  • No statistically significant differences were observed in inflammatory biomarker levels (CRP, IL-6, MPO, sCD40L) among the treatment groups.
  • Measurements at baseline, hospital discharge, and 4 weeks showed comparable results across ticagrelor and clopidogrel arms.

Conclusions:

  • Ticagrelor and clopidogrel demonstrated similar effects on the measured inflammatory biomarkers in NSTE-ACS patients.
  • The study did not find a significant difference in the anti-inflammatory impact of ticagrelor compared to clopidogrel for CRP, IL-6, MPO, and sCD40L.
Abstract

More Related Videos

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

On-Chip Endothelial Inflammatory Phenotyping12:43

On-Chip Endothelial Inflammatory Phenotyping

Published on: July 21, 2012

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...